TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3543092

Group type: EXPERIMENTAL
Intervention: Diltiazem (90 to 360 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 to 120 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of diltiazem and nifedipine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 15
Study: 31811562

Group type: EXPERIMENTAL
Intervention: Apheresis therapy (twice per month for 12 months)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (no apheresis treatment)
Number of subjects: 164
Study: 30655182

Group type: EXPERIMENTAL
Intervention: Self-reported sexual activity (yes/no)
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Erectile function measured by the 5-item International Index of Erectile Function (IIEF-5)
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP)
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP)
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) in sexually active participants
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) in sexually active participants
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP) in sexually active participants
Number of subjects: 1255
Study: 28901538

Group type: EXPERIMENTAL
Intervention: Rested state
Number of subjects: 19

Group type: COMPARATOR
Intervention: Fatigued state
Number of subjects: 19

Group type: COMPARATOR
Intervention: Self-ratings of clinical performance
Number of subjects: 19
Study: 26126079

Group type: EXPERIMENTAL
Intervention: Telehealth services in home healthcare agencies
Number of subjects: 1582

Group type: EXPERIMENTAL
Intervention: Telehealth services in assisted living facilities
Number of subjects: 1582

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1582
Study: 23249916

Group type: EXPERIMENTAL
Intervention: Extended infant nevirapine (NVP) administration
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Maternal antiretroviral treatment regimen (including NVP or efavirenz)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No maternal antiretroviral treatment
Number of subjects: 38
Study: 21778674

Group type: EXPERIMENTAL
Intervention: Hybrid training method (HYB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isometric electrical stimulation (ES)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CN)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups (HYB, ES, CN)
Number of subjects: 30
Study: 19564304

Group type: EXPERIMENTAL
Intervention: Moderate-dose methylphenidate (0.6 mg/kg; 20 mg twice daily maximum)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Low-dose methylphenidate (0.3 mg/kg; 10 mg twice daily maximum)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Baseline (before treatment)
Number of subjects: 103
Study: 17083767

Group type: EXPERIMENTAL
Intervention: Initial combination therapy with methotrexate, sulphasalazine, and tapered high dose of prednisone
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Initial combination therapy with methotrexate and infliximab
Number of subjects: 508

Group type: COMPARATOR
Intervention: Sequential monotherapy
Number of subjects: 508

Group type: COMPARATOR
Intervention: Step up to combination therapy starting with methotrexate
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: All treatment strategies
Number of subjects: 508
Study: 14760157

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis (CF)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 302
Study: 11313304

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: pANCA
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: sANCA
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: LTA NcoI‐TNFc‐aa13L‐aa26 haplotype 1‐1‐1‐1
Number of subjects: 59
Study: 9202949

Group type: EXPERIMENTAL
Intervention: 6% glucose-electrolyte solution (GS)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 6% maltodextrin solution
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 6% maltodextrin-electrolyte solution
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: mineral water
Number of subjects: 6

Group type: COMPARATOR
Intervention: No fluid (control)
Number of subjects: 6
Study: 7956570

Group type: EXPERIMENTAL
Intervention: Anal sphincter reconstruction using an overlapping muscle repair
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Continuous pull‐out manometric technique and PNTML
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pudendal nerve terminal motor latency (PNTML) assessment
Number of subjects: 14
Study: 3440105

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg) given as enteric-coated granules
Number of subjects: 12

Group type: COMPARATOR
Intervention: Antacid (10 ml, buffering capacity 56.6 mmol 10 ml‐1)
Number of subjects: 12
Study: 31873772

Group type: EXPERIMENTAL
Intervention: rhTNFR‐Fc plus MTX
Number of subjects: 466

Group type: COMPARATOR
Intervention: rhTNFR‐Fc plus placebo
Number of subjects: 466
Study: 31127974

Group type: EXPERIMENTAL
Intervention: PsychoEducation, Paced Respiration, and Relaxation (PEPRR)
Number of subjects: 155

Group type: COMPARATOR
Intervention: enhanced treatment as usual (eTAU)
Number of subjects: 155
Study: 27933462

Group type: EXPERIMENTAL
Intervention: Healthy Beginning Initiative (HBI)
Number of subjects: 2498

Group type: COMPARATOR
Intervention: Standard of care referral to a health facility (CG)
Number of subjects: 2498
Study: 25946501

Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Message
Number of subjects: 76

Group type: COMPARATOR
Intervention: Silence (Control)
Number of subjects: 76
Study: 23299762

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Running (HIIR) - 10 × 1 min running intervals at 100% maximal aerobic speed with 1 min recovery between intervals
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (CON) - resting
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Running (HIIR)
Number of subjects: 15
Study: 21981454

Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mustard oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olvanil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cinnamaldehyde
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anandamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Menthol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 18665032

Group type: EXPERIMENTAL
Intervention: Mupirocin ointment therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ofloxacin ear drops
Number of subjects: 26
Study: 16715358

Group type: EXPERIMENTAL
Intervention: Fixed dose of pertuzumab (420 or 1050 mg)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Weight-based dosing (0.5-15 mg/kg)
Number of subjects: 153

Group type: COMPARATOR
Intervention: BSA-based dosing
Number of subjects: 153
Study: 12559533

Group type: EXPERIMENTAL
Intervention: Clopidogrel 1 x 300 mg as a loading dose, and 1 x 75 mg per day thereafter
Number of subjects: 158

Group type: COMPARATOR
Intervention: Ticlopidine 2 x 250 mg daily
Number of subjects: 158
Study: 11255054

Group type: EXPERIMENTAL
Intervention: Healon5 (sodium hyaluronate 2.3%)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Viscoat (sodium hyaluronate 3.0%-chondroitin sulfate 4.0%)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Healon5
Number of subjects: 90

Group type: COMPARATOR
Intervention: Viscoat
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Healon5 and Viscoat
Number of subjects: 90
Study: 9424002

Group type: EXPERIMENTAL
Intervention: High dose radiation therapy (60 Gy continuously) and daily cisplatin (6 mg/sqm/day)
Number of subjects: 23
Study: 8276050

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of ramipril and propranolol
Number of subjects: 12
Study: 3719066

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Additional accumulated data
Number of subjects: 0
Study: 30611113

Group type: EXPERIMENTAL
Intervention: The Pink Kit Method for Birthing Better® (CKT, 2001), a multi-media, skills-based and self-directed childbirth preparation programme.
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control groups (not specified in detail).
Number of subjects: 182
Study: 28391278

Group type: EXPERIMENTAL
Intervention: Remote assessment via high-quality videoconferencing (HQ-VTC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bedside assessment
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Remote assessment via HQ-VTC
Number of subjects: 90
Study: 24907502

Group type: EXPERIMENTAL
Intervention: Medium-dose oral budesonide suspension (OBS)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: High-dose oral budesonide suspension (OBS)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Low-dose oral budesonide suspension (OBS)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 23592260

Group type: EXPERIMENTAL
Intervention: Circumcision (intervention group)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Uncircumcised (control group)
Number of subjects: 156
Study: 21334854

Group type: EXPERIMENTAL
Intervention: Folate 2mg/d
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 19050877

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of autologous mononuclear bone marrow cells (BMC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study: 17130431

Group type: EXPERIMENTAL
Intervention: Orally administered CC chemokine receptor 1 (CCR1) antagonist
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 15313289

Group type: EXPERIMENTAL
Intervention: Textured edge IOL (Alcon MA60AC)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Round-anterior, sloped-sided edge IOL (AMO AR40e)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both IOLs
Number of subjects: 54
Study: 10912264

Group type: EXPERIMENTAL
Intervention: Treatment of nasal allergy for a period of at least four months
Number of subjects: 52
Study: 9195540

Group type: EXPERIMENTAL
Intervention: Disease targeted measures
Number of subjects: 0
Study: 8141724

Group type: EXPERIMENTAL
Intervention: Hirulog
Number of subjects: 400

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 400
Study: 2883406

Group type: EXPERIMENTAL
Intervention: 0.6 g/kg intravenous immunoglobulin
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.2 g/kg intravenous immunoglobulin
Number of subjects: 12
Study: 29916860

Group type: EXPERIMENTAL
Intervention: LAS VEGAS risk score
Number of subjects: 6063
Study: 26700254

Group type: EXPERIMENTAL
Intervention: Methylene blue staining (Group 1)
Number of subjects: 144

Group type: COMPARATOR
Intervention: No staining (Group 2)
Number of subjects: 144
Study: 24215475

Group type: EXPERIMENTAL
Intervention: Topical 5-aminolevulinic acid (ALA) photodynamic therapy (PDT) with light dose of 70 J/cm2
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Topical 5-aminolevulinic acid (ALA) photodynamic therapy (PDT) with light dose of 100 J/cm2
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Adverse events of ALA-PDT
Number of subjects: 38
Study: 22503646

Group type: EXPERIMENTAL
Intervention: Physical activity and nutrition program for seniors (PANS)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group (small incentives for questionnaires)
Number of subjects: 248
Study: 20102925

Group type: EXPERIMENTAL
Intervention: 3-D speckle tracking strain imaging system
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard 2-D strain datasets
Number of subjects: 64
Study: 18031294

Group type: EXPERIMENTAL
Intervention: Flow cytometry-based VWF:RCo assay
Number of subjects: 84
Study: 16120888

Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 10

Group type: COMPARATOR
Intervention: Modified conventional glucose control
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 10
Study: 12115321

Group type: EXPERIMENTAL
Intervention: Perilymphatic recombinant IL‐2 (rIL‐2) administered at 5000 units daily for 10 days before surgery and monthly for 1 year after surgery.
Number of subjects: 202

Group type: COMPARATOR
Intervention: Surgery and radiotherapy (Control group).
Number of subjects: 202
Study: 10336919

Group type: EXPERIMENTAL
Intervention: Captopril plus losartan (group B)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Captopril (group A)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Losartan (group C)
Number of subjects: 99
Study: 7579136

Group type: EXPERIMENTAL
Intervention: 0.15 IU insulin kg‐1
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 8
Study: 1537779

Group type: EXPERIMENTAL
Intervention: Nortriptyline (active treatment)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 50
Study: 6393818

Group type: EXPERIMENTAL
Intervention: Buprenorphine 4-6 micrograms/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 80
Study: 30789780

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 308
Study: 29377842

Group type: EXPERIMENTAL
Intervention: Lipid-based eye drops
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sodium hyaluronate-based eye drops
Number of subjects: 30
Study: 24048759

Group type: EXPERIMENTAL
Intervention: Ultrasonically activated shears (UAS)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 253
Study: 22613136

Group type: EXPERIMENTAL
Intervention: abciximab infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo infusion
Number of subjects: 60
Study: 19272785

Group type: EXPERIMENTAL
Intervention: Posthorax sternum vest (group A)
Number of subjects: 455

Group type: COMPARATOR
Intervention: No vest (group B)
Number of subjects: 455

Group type: COMPARATOR
Intervention: No vest (group C)
Number of subjects: 455
Study: 17697305

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg/kg bolus and infusion at a rate of 0.7 microg/kg/h)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not receiving dexmedetomidine)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (D and C)
Number of subjects: 24
Study: 15352143

Group type: EXPERIMENTAL
Intervention: Individualized advice on non‐pharmacological strategies from an extended practice nurse
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual care (assessment by a geriatrician)
Number of subjects: 71
Study: 11642510

Group type: EXPERIMENTAL
Intervention: Serum transferrin receptor (s‐TfR) levels in RA patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Serum erythropoietin (EPO) levels in RA patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Correlation of s‐TfR levels with red blood cell count, serum iron level, and haemoglobin concentration
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Correlation of s‐TfR levels with ESR and serum EPO levels
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Correlation of s‐TfR levels with markers of inflammation
Number of subjects: 50
Study: 11367653

Group type: EXPERIMENTAL
Intervention: Feiyan Chuansou Oral Liquid (FCOL)
Number of subjects: 0
Study: 7882780

Group type: EXPERIMENTAL
Intervention: Terminal warm blood cardioplegia (TWBC)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Continuous warm blood cardioplegia (CWBC)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Cold blood cardioplegia (CBC)
Number of subjects: 69

Group type: COMPARATOR
Intervention: St. Thomas group (CC)
Number of subjects: 69
Study: 2975567

Group type: EXPERIMENTAL
Intervention: Three times daily pen regimen with human ultralente at night
Number of subjects: 78

Group type: COMPARATOR
Intervention: Twice daily insulin regimen
Number of subjects: 78
Study: 29665013

Group type: EXPERIMENTAL
Intervention: N-BR (normoxic bed rest)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: H-BR (hypoxic bed rest)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: H-AMB (hypoxic ambulatory confinement)
Number of subjects: 11
Study: 25952532

Group type: EXPERIMENTAL
Intervention: Basal-prandial insulin (stepwise addition of insulin glulisine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Premixed insulin (insulin aspart/insulin aspart protamine 30/70 starting with 6IU twice daily)
Number of subjects: 0
Study: 24710917

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 50

Group type: COMPARATOR
Intervention: No nicotine gum (control)
Number of subjects: 50
Study: 23314694

Group type: EXPERIMENTAL
Intervention: 2.0 μg/kg fentanyl
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 4.0 μg/kg fentanyl
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 90
Study: 20498403

Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg plus docetaxel 100 mg/m(2)
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 mg/kg plus docetaxel 100 mg/m(2)
Number of subjects: 736

Group type: COMPARATOR
Intervention: Docetaxel 100 mg/m(2) plus placebo
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 mg/kg
Number of subjects: 736
Study: 19098989

Group type: EXPERIMENTAL
Intervention: Monthly artesunate plus amodiaquine (AS+AQ)
Number of subjects: 2451

Group type: EXPERIMENTAL
Intervention: Bimonthly sulphadoxine-pyrimethamine (SP)
Number of subjects: 2451

Group type: EXPERIMENTAL
Intervention: Bimonthly artesunate plus amodiaquine (AS+AQ)
Number of subjects: 2451

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2451
Study: 15908136

Group type: EXPERIMENTAL
Intervention: Self-reported substance abuse treatment contact after enrollment
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Biochemical evidence of continued cocaine use
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Race, hair cocaine level, and opiates in hair
Number of subjects: 525
Study: 14620390

Group type: EXPERIMENTAL
Intervention: Trizivir
Number of subjects: 195

Group type: COMPARATOR
Intervention: Combivir-ABC
Number of subjects: 195
Study: 10720292

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Modafinil (both doses)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study: 8704682

Group type: EXPERIMENTAL
Intervention: BU/CY2 conditioning regimen
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: BU/CY2 conditioning regimen with T cell depletion
Number of subjects: 52
Study: 1465034

Group type: EXPERIMENTAL
Intervention: 2 mg 17 beta‐oestradiol and different doses of progesterone (50, 100 or 200 mg)
Number of subjects: 30
Study: 3882774

Group type: EXPERIMENTAL
Intervention: clovoxamine
Number of subjects: 42

Group type: COMPARATOR
Intervention: amitriptyline
Number of subjects: 42
Study: 30629675

Group type: EXPERIMENTAL
Intervention: New PermaNet2.0 LLINs distributed to households in October 2014
Number of subjects: 17142

Group type: EXPERIMENTAL
Intervention: LLIN use during the first year (week 1-52)
Number of subjects: 17142

Group type: EXPERIMENTAL
Intervention: LLIN use during the second year (week 53-104)
Number of subjects: 17142

Group type: EXPERIMENTAL
Intervention: Age group comparison for LLIN use
Number of subjects: 17142

Group type: EXPERIMENTAL
Intervention: Household head educational status comparison for LLIN use
Number of subjects: 17142

Group type: EXPERIMENTAL
Intervention: Family size comparison for LLIN use
Number of subjects: 17142
Study: 29907581

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 12221

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 12221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12221

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg (EMPA-REG H2H-SU trial)
Number of subjects: 12221

Group type: COMPARATOR
Intervention: Glimepiride (EMPA-REG H2H-SU trial)
Number of subjects: 12221
Study: 26465829

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (233 mg zinc gluconate containing 30 mg zinc) for 6 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 50
Study: 24671361

Group type: EXPERIMENTAL
Intervention: Electronic reminders during the second period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no electronic reminders)
Number of subjects: 0
Study: 23065038

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 469

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469
Study: 20650926

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17543812

Group type: EXPERIMENTAL
Intervention: Levobupivacaine infusion (50 hours)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Saline infusion (50 hours)
Number of subjects: 84
Study: 16118753

Group type: EXPERIMENTAL
Intervention: Robotic-assisted total hip arthroplasty
Number of subjects: 71

Group type: COMPARATOR
Intervention: Conventional total hip arthroplasty
Number of subjects: 71
Study: 11982742

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 60 mg day -1
Number of subjects: 14
Study: 10441040

Group type: EXPERIMENTAL
Intervention: 25 mg/kg (b.w.) of nicotinamide (NA)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 50 mg/kg (b.w.) of nicotinamide (NA)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both doses of nicotinamide (25 mg/kg and 50 mg/kg)
Number of subjects: 74
Study: 8929228

Group type: EXPERIMENTAL
Intervention: Bifemelane (CAS 90293‐01‐9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2077983

Group type: EXPERIMENTAL
Intervention: Midazolam 0.4 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diazepam 0.75 mg/kg
Number of subjects: 60